Noticias y Actividades de Ironwood Pharmaceuticals

Ironwood Pharmaceuticals es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Ironwood Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización IRWD (US).

Ver el organigrama con sus 20 ejecutivos principales

Biografías más buscadas en Ironwood Pharmaceuticals

• Thomas McCourt, Chief Executive Officer and Director
• Catherine Moukheibir, Director
• Julie McHugh, Chairman of the Board

Recientes movimientos de ejecutivos en Ironwood Pharmaceuticals

• Tammi Gaskins que ha sido Vice President of Brand Management, ha ascendido a Senior Vice President and Chief Commercial Officer  (noticia publicada el 30 de enero de 2025).
• Sravan Emany, Senior Vice President, Chief Financial Officer and Chief Operations Officer, ha dejado la empresa  (noticia publicada el 30 de diciembre de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals tiene 1.838 competidores entre los que se incluyen Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) y Sanofi (Francia).

Popular M&A news in Farmacia

• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (publicado el 16 de junio de 2025).
• Juvenescence acaba de anunciar una recaudación de fondos de 76 millones de dólares. (publicado el 22 de mayo de 2025).
• Kincell Bio acaba de anunciar una recaudación de fondos de 22 millones de dólares. (publicado el 22 de mayo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Amanda Moore - Vice President, Program Leadership and Clinical Operations en Abeona Therapeutics
• Keiichi Ando - Independent Non-Executive Director en Shionogi

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Ironwood Pharmaceuticals

• Ironwood Pharmaceuticals Reports First Quarter 2025 Results
• Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
• Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
• Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
• Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
• Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
• Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
• Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
• Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
• Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
• View more press releases Close

Redes sociales sobre Ironwood Pharmaceuticals

• Ironwood Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Ironwood Pharmaceuticals en LinkedIn, Twitter y YouTube